Department of Radiation Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):297-303. doi: 10.1016/j.ijrobp.2013.06.004. Epub 2013 Aug 1.
Hodgkin lymphoma (HL) survivors are at an increased risk of stroke because of carotid artery irradiation. However, for early-stage HL involved node radiation therapy (INRT) reduces the volume of normal tissue exposed to high doses. Here, we evaluate 3-dimensional conformal radiation therapy (3D-CRT), volumetric-modulated arc therapy (VMAT), and proton therapy (PT) delivered as INRT along with the extensive mantle field (MF) by comparing doses to the carotid arteries and corresponding risk estimates.
We included a cohort of 46 supradiaphragmatic stage I-II classical HL patients. All patients were initially treated with chemotherapy and INRT delivered as 3D-CRT (30 Gy). For each patient, we simulated MF (36 Gy) and INRT plans using VMAT and PT (30 Gy). Linear dose-response curves for the 20-, 25-, and 30-year risk of stroke were derived from published HL data. Risks of stroke with each technique were calculated for all patients. Statistical analyses were performed with repeated measures analysis of variance.
The mean doses to the right and left common carotid artery were significantly lower with modern treatment compared with MF, with substantial patient variability. The estimated excess risk of stroke after 20, 25, and 30 years was 0.6%, 0.86%, and 1.3% for 3D-CRT; 0.67%, 0.96%, and 1.47% for VMAT; 0.61%, 0.96%, and 1.33% for PT; and 1.3%, 1.72%, and 2.61% for MF.
INRT reduces the dose delivered to the carotid arteries and corresponding estimated risk of stroke for HL survivors. Even for the subset of patients with lymphoma close to the carotid arteries, the estimated risk is low.
霍奇金淋巴瘤(HL)患者由于颈动脉照射而中风风险增加。然而,对于早期 HL 累及淋巴结放疗(INRT)可减少暴露于高剂量的正常组织体积。在这里,我们通过比较颈动脉剂量和相应的风险估计值,评估了作为 INRT 给予的 3 维适形放疗(3D-CRT)、容积调制弧形治疗(VMAT)和质子治疗(PT),以及广泛的斗篷野(MF)。
我们纳入了 46 例膈上 I-II 期经典 HL 患者队列。所有患者最初均接受化疗和 INRT 治疗,采用 3D-CRT(30 Gy)。对每位患者,我们采用 VMAT 和 PT(30 Gy)模拟 MF(36 Gy)和 INRT 计划。从已发表的 HL 数据中得出了 20 年、25 年和 30 年中风风险的线性剂量反应曲线。计算了所有患者的每种技术的中风风险。采用重复测量方差分析进行统计分析。
与 MF 相比,现代治疗方法使右、左颈总动脉的平均剂量明显降低,且患者间存在较大差异。估计 20 年、25 年和 30 年后中风的额外风险为 3D-CRT 为 0.6%、0.86%和 1.3%;VMAT 为 0.67%、0.96%和 1.47%;PT 为 0.61%、0.96%和 1.33%;MF 为 1.3%、1.72%和 2.61%。
INRT 降低了 HL 幸存者颈动脉的剂量和相应的中风风险。即使对于靠近颈动脉的淋巴瘤患者亚组,估计风险也较低。